Comparing the effects of two medications on healthy individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the pharmacokinetic characteristics and safety profiles of a medication called PA-111 compared to its coadministration with PA-111A in healthy subjects. The primary goal is to understand how these medications are processed in the body. Participants will be monitored for safety and any adverse effects during the study. The trial is designed for individuals who meet specific health criteria and are not currently involved in other clinical studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit

Exclusion Criteria:

* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
* Other exclusions applied

Where it's running

• H Plus Yangji Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: JeongEun Park
• Email: parkje@addpharma.co.kr
• Phone: +82-31-891-6989

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MWX203: a medicine for mixed dyslipidemia given alone or with Inclisiran

  This phase 2 study tests MWX203 alone or with Inclisiran in adults with mixed dyslipidemia who don’t reach lipid goals on statins.

  Recruiting Phase 2 Shanghai Minwei Biotechnology Co., Ltd · Beijing, Beijing Municipality · NCT07803822

• Obicetrapib vs. bempedoic acid for high-risk high cholesterol patients

  This phase 3 study tests whether obicetrapib can lower LDL-C more than bempedoic acid in adults with primary non-familial hypercholesterolemia or mixed dyslipidemia who still have high LDL-C despite maximum tolerated therapy.

  Recruiting Phase 3 A. Menarini International Licensing S.A. · Stockton-on-Tees · NCT07614958

• Bempedoic Acid With Ezetiimibe in Adults with High Cholesterol or Mixed Dyslipidemia

  This study tests bempedoic acid alone or with ezetimibe in real-world adults with primary hypercholesterolemia or mixed dyslipidemia to see how safe and effective it is in routine care.

  Recruiting at 38 sites Daiichi Sankyo · Belo Horizonte and 37 other locations · NCT07206472

• Evaluating the effectiveness and safety of a combination medication for cholesterol management

  This study is testing a new combination medication for cholesterol management to see if it works better and is safe for people who need a change in their current cholesterol treatment.

  Recruiting Boryung Pharmaceutical Co., Ltd · Seoul · NCT06314919

• Evaluating the effectiveness and safety of AD-218 for mixed dyslipidemia

  This study is testing if a new drug called AD-218 can help people with mixed dyslipidemia improve their cholesterol levels and overall health.

  Recruiting Phase 3 Addpharma Inc. · Daegu, Nam-gu · NCT05400317

• Leqvio (inclisiran) post-marketing surveillance in Korea

  This will see if Leqvio (inclisiran) is safe and lowers LDL cholesterol for adults in Korea with primary hypercholesterolemia or mixed dyslipidemia who are prescribed it in routine care.

  Recruiting at 4 sites Novartis · Yangsan, Gyeongsangnam-do and 3 other locations · NCT06770543

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.